Abstract
Alzheimers disease, as well as most of other neurodegenerative disorders, is characterized by the deposition of insoluble proteinaceous aggregates. Hence, any intervention aimed at reducing this process could be envisioned as a therapeutic way to slow down the disease. In the case of Alzheimers disease, the culprit protein is the 40-43 amino acidlong amyloid b peptide (Aβ). This fragment is generated from the β-amyloid precursor protein (bAPP) by two distinct enzymes, namely the β- and the γ-secretases. In the past years, a tremendous effort has been made to develop potent and specific inhibitors of these proteolytic activities. Beside these Aβ-forming proteases, a third cleavage performed by the socalled α-secretase takes place in the middle of the Aβ sequence and not only precludes its formation but also generates the secreted product sAPPα that possesses neurotrophic and neuroprotective properties. This beneficial cleavage has been shown to be strongly upregulated by protein kinase C (PKC) agonists and to be, at least partially, triggered by ADAM proteases (A Disintegrin And Metalloprotease). Recently, a proteolytic attack with similar characteristics has been shown to occur in the middle of the “toxicrdquo; 106-126 domain of the prion protein (PrPc), which PrPsc isoform is the causative agent of transmissible spongiform encephalopathies. As both Ab and PrP(106-126) trigger neurotoxicity and cell death, this ADAM-dependent proteolytic attack could represent a valuable therapeutic target in order to deplete cells from these endogenous “toxins”and prevent the associated aggregates usually detected in affected brains.
Keywords: ADAM Proteases, 40-43 amino acidlong, protein kinase C (PKC), encephalopathies, prion protein (PrPc)
Current Alzheimer Research
Title: ADAM Proteases: Protective Role in Alzheimers and Prion Diseases ?
Volume: 1 Issue: 3
Author(s): Bruno Vincent
Affiliation:
Keywords: ADAM Proteases, 40-43 amino acidlong, protein kinase C (PKC), encephalopathies, prion protein (PrPc)
Abstract: Alzheimers disease, as well as most of other neurodegenerative disorders, is characterized by the deposition of insoluble proteinaceous aggregates. Hence, any intervention aimed at reducing this process could be envisioned as a therapeutic way to slow down the disease. In the case of Alzheimers disease, the culprit protein is the 40-43 amino acidlong amyloid b peptide (Aβ). This fragment is generated from the β-amyloid precursor protein (bAPP) by two distinct enzymes, namely the β- and the γ-secretases. In the past years, a tremendous effort has been made to develop potent and specific inhibitors of these proteolytic activities. Beside these Aβ-forming proteases, a third cleavage performed by the socalled α-secretase takes place in the middle of the Aβ sequence and not only precludes its formation but also generates the secreted product sAPPα that possesses neurotrophic and neuroprotective properties. This beneficial cleavage has been shown to be strongly upregulated by protein kinase C (PKC) agonists and to be, at least partially, triggered by ADAM proteases (A Disintegrin And Metalloprotease). Recently, a proteolytic attack with similar characteristics has been shown to occur in the middle of the “toxicrdquo; 106-126 domain of the prion protein (PrPc), which PrPsc isoform is the causative agent of transmissible spongiform encephalopathies. As both Ab and PrP(106-126) trigger neurotoxicity and cell death, this ADAM-dependent proteolytic attack could represent a valuable therapeutic target in order to deplete cells from these endogenous “toxins”and prevent the associated aggregates usually detected in affected brains.
Export Options
About this article
Cite this article as:
Vincent Bruno, ADAM Proteases: Protective Role in Alzheimers and Prion Diseases ?, Current Alzheimer Research 2004; 1 (3) . https://dx.doi.org/10.2174/1567205043332072
DOI https://dx.doi.org/10.2174/1567205043332072 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Therapeutic Prospects of PPARs in Psychiatric Disorders: A Comprehensive Review
Current Drug Targets Proteomic Approaches Contributing to the Understanding of Neurodegenerative Diseases: Focus on Alzheimers Disease
Current Proteomics Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews NAD(P) Biosynthesis Enzymes as Potential Targets for Selective Drug Design
Current Medicinal Chemistry Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review
Recent Patents on Regenerative Medicine Recent Patents on Drugs Addressing Neurodegenerative Diseases
Recent Patents on Biomarkers Combining Feature Extraction Methods to Assist the Diagnosis of Alzheimer’s Disease
Current Alzheimer Research In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy Protein Folding and Misfolding, Endoplasmic Reticulum Stress in Neurodegenerative Diseases: in Trace of Novel Drug Targets
Current Protein & Peptide Science Editorial [Hot Topic: Amyloid-Associated Disease Mechanisms in Alzheimers Disease (Guest Editor: Jeroen J.M. Hoozemans)]
Current Drug Targets - CNS & Neurological Disorders Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory
Current Pharmaceutical Design Dangerous Liaisons: Tau Interaction with Muscarinic Receptors
Current Alzheimer Research Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Aging Affects Nicotinic Acetylcholine Receptors in Brain
Central Nervous System Agents in Medicinal Chemistry Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool
Current Protein & Peptide Science Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms
CNS & Neurological Disorders - Drug Targets Neuroprotective Role of Agmatine in Neurological Diseases
Current Neuropharmacology